7/28/2023 12:51:53 PM - There was a "negative reversal" on the prior session after hitting another new 52-week high. The prior mid-day report noted - <i>"Resistance remains due to overhead supply up to the $99 level. Reported Jun &#39;23 quarterly earnings +22% versus the year ago period, below the fact-based investment system&#39;s +25% minimum earnings guideline (C criteria). A 2:1 split impacted share price on 10/02/21. This Israel-based Medical - Systems/Equipment firm completed its $14 IPO on 8/08/19."</i><br><hr>7/27/2023 12:40:59 PM - Hit another new 52-week high with today&#39;s gain backed by higher volume. Resistance remains due to overhead supply up to the $99 level. Reported Jun &#39;23 quarterly earnings +22% versus the year ago period, below the fact-based investment system&#39;s +25% minimum earnings guideline (C criteria). A 2:1 split impacted share price on 10/02/21. This Israel-based Medical - Systems/Equipment firm completed its $14 IPO on 8/08/19.<br><hr>7/13/2023 12:48:16 PM - Hit another new 52-week high today following 4 consecutive gains backed by higher volume. Resistance remains due to overhead supply up to the $99 level. Reported Mar &#39;23 quarterly earnings +30% on +23% sales revenues versus the year ago period, an improvement after 4 consecutive quarterly comparisons below the fact-based investment system&#39;s +25% minimum earnings guideline (C criteria). A 2:1 split impacted share price on 10/02/21. This Israel-based Medical - Systems/Equipment firm completed its $14 IPO on 8/08/19.<br><hr>7/12/2023 12:25:40 PM - Hitting a new 52-week high with today&#39;s gap up and 4th consecutive gain backed by higher volume. Resistance remains due to overhead supply up to the $99 level. Reported Mar &#39;23 quarterly earnings +30% on +23% sales revenues versus the year ago period, an improvement after 4 consecutive quarterly comparisons below the fact-based investment system&#39;s +25% minimum earnings guideline (C criteria). A 2:1 split impacted share price on 10/02/21. This Israel-based Medical - Systems/Equipment firm completed its $14 IPO on 8/08/19.<br><hr>7/10/2023 12:38:49 PM - Perched within close striking distance of its 52-week high with today&#39;s gain. Reported Mar &#39;23 quarterly earnings +30% on +23% sales revenues versus the year ago period, an improvement after 4 consecutive quarterly comparisons below the fact-based investment system&#39;s +25% minimum earnings guideline (C criteria). A 2:1 split impacted share price on 10/02/21. This Israel-based Medical -  Systems/Equipment firm completed its $14 IPO on 8/08/19.<br><hr>10/26/2021 12:30:32 PM - Hovering near its all-time high today. It did not form a sound base but found support above its 50 DMA line ($72.40) on pullbacks. A 2:1 split impacted share price on 10/02/21. Reported Sep &#39;21 quarterly earnings +77% on +58% sales revenues versus the year ago period, marking its 4th consecutive quarterly comparison above the fact-based investment system&#39;s +25% minimum earnings guideline (C criteria). This Israel-based Medical -  Systems/Equipment firm completed its $14 IPO on 8/08/19.<br><hr>10/20/2021 12:43:25 PM - Touched a new all-time high today but reversed into the red. It did not form a sound base but found support above its 50 DMA line ($69.89) on pullbacks. A 2:1 split impacted share price on 10/02/21. Reported Jun &#39;21 quarterly earnings +325% on +184% sales revenues versus the year ago period, marking its 4th consecutive quarterly comparison above the fact-based investment system&#39;s +25% minimum earnings guideline (C criteria). This Israel-based Medical -  Systems/Equipment firm completed its $14 IPO on 8/08/19.<br><hr>10/14/2021 12:46:17 PM - Very extended from any sound base. Found support above its 50 DMA line ($67.70) on pullbacks. A 2:1 split impacted share price on 10/02/21. Reported Jun &#39;21 quarterly earnings +325% on +184% sales revenues versus the year ago period, marking its 4th consecutive quarterly comparison above the fact-based investment system&#39;s +25% minimum earnings guideline (C criteria). This Israel-based Medical -  Systems/Equipment firm completed its $14 IPO on 8/08/19.<br><hr>10/13/2021 12:16:44 PM - A 2:1 split impacted share price on 10/02/21. Very extended from any sound base. Found support above its 50 DMA line ($67) on pullbacks. Reported Jun &#39;21 quarterly earnings +325% on +184% sales revenues versus the year ago period, marking its 4th consecutive quarterly comparison above the fact-based investment system&#39;s +25% minimum earnings guideline (C criteria). This Israel-based Medical -  Systems/Equipment firm completed its $14 IPO on 8/08/19.<br><hr>10/1/2021 12:28:44 PM - A 2:1 split impacted share price today. Very extended from any sound base. Found support above its 50 DMA line ($64) on prior pullbacks. Reported Jun &#39;21 quarterly earnings +325% on +184% sales revenues versus the year ago period, marking its 4th consecutive quarterly comparison above the fact-based investment system&#39;s +25% minimum earnings guideline (C criteria). This Israel-based Medical -  Systems/Equipment firm completed its $14 IPO on 8/08/19.<br><hr>9/30/2021 12:27:19 PM - Very extended from any sound base. Found support above its 50 DMA line ($128) on prior pullbacks. Reported Jun &#39;21 quarterly earnings +325% on +184% sales revenues versus the year ago period, marking its 4th consecutive quarterly comparison above the fact-based investment system&#39;s +25% minimum earnings guideline (C criteria). This Israel-based Medical -  Systems/Equipment firm completed its $14 IPO on 8/08/19.<br><hr>9/29/2021 12:41:24 PM - Very extended from any sound base. Found support above its 50 DMA line ($127) on prior pullbacks. Reported Jun &#39;21 quarterly earnings +325% on +184% sales revenues versus the year ago period, marking its 4th consecutive quarterly comparison above the fact-based investment system&#39;s +25% minimum earnings guideline (C criteria). This Israel-based Medical -  Systems/Equipment firm completed its $14 IPO on 8/08/19.<br><hr>9/27/2021 1:15:13 PM - Pulling back from its all-time high today following 4 consecutive volume-driven gains, getting very extended from any sound base. Found support above its 50 DMA line during its ongoing ascent. Reported Jun &#39;21 quarterly earnings +325% on +184% sales revenues versus the year ago period, marking its 4th consecutive quarterly comparison above the fact-based investment system&#39;s +25% minimum earnings guideline (C criteria). This Israel-based Medical -  Systems/Equipment firm completed its $14 IPO on 8/08/19.<br><hr>9/24/2021 12:15:20 PM - Hitting yet another new all-time high with today&#39;s 4th consecutive volume-driven gain, getting very extended from any sound base. Found support above its 50 DMA line during its ongoing ascent. Reported Jun &#39;21 quarterly earnings +325% on +184% sales revenues versus the year ago period, marking its 4th consecutive quarterly comparison above the fact-based investment system&#39;s +25% minimum earnings guideline (C criteria). This Israel-based Medical -  Systems/Equipment firm completed its $14 IPO on 8/08/19.<br><hr>9/23/2021 12:09:59 PM - Hitting yet another new all-time high with today&#39;s 3rd consecutive volume-driven gain, getting very extended from any sound base. Found support above its 50 DMA line during its ongoing ascent. Reported Jun &#39;21 quarterly earnings +325% on +184% sales revenues versus the year ago period, marking its 4th consecutive quarterly comparison above the fact-based investment system&#39;s +25% minimum earnings guideline (C criteria). This Israel-based Medical -  Systems/Equipment firm completed its $14 IPO on 8/08/19.<br><hr>9/22/2021 12:36:57 PM - Hitting yet another new all-time high with today&#39;s gain after a gap up big volume-driven gain on the prior session, getting very extended from any sound base. Found support above its 50 DMA line during its ongoing ascent. Reported Jun &#39;21 quarterly earnings +325% on +184% sales revenues versus the year ago period, marking its 4th consecutive quarterly comparison above the fact-based investment system&#39;s +25% minimum earnings guideline (C criteria). This Israel-based Medical -  Systems/Equipment firm completed its $14 IPO on 8/08/19.<br><hr>9/21/2021 12:28:28 PM - Hitting yet another new all-time high with a gap up big volume-driven gain today, getting very extended from any sound base. Found support above its 50 DMA line during its ongoing ascent. Reported Jun &#39;21 quarterly earnings +325% on +184% sales revenues versus the year ago period, marking its 4th consecutive quarterly comparison above the fact-based investment system&#39;s +25% minimum earnings guideline (C criteria). This Israel-based Medical -  Systems/Equipment firm completed its $14 IPO on 8/08/19.<br><hr>9/20/2021 12:52:01 PM - Hit another new all-time high with a big volume-driven gain on the prior session, getting very extended from any sound base. Found support above its 50 DMA line during its ongoing ascent. Reported Jun &#39;21 quarterly earnings +325% on +184% sales revenues versus the year ago period, marking its 4th consecutive quarterly comparison above the fact-based investment system&#39;s +25% minimum earnings guideline (C criteria). This Israel-based Medical -  Systems/Equipment firm completed its $14 IPO on 8/08/19.<br><hr>9/17/2021 1:03:15 PM - Hitting another new all-time high with today&#39;s big volume-driven gain, getting very extended from any sound base. Found support above its 50 DMA line during its ongoing ascent. Reported Jun &#39;21 quarterly earnings +325% on +184% sales revenues versus the year ago period, marking its 4th consecutive quarterly comparison above the fact-based investment system&#39;s +25% minimum earnings guideline (C criteria). This Israel-based Medical -  Systems/Equipment firm completed its $14 IPO on 8/08/19.<br><hr>9/14/2021 12:39:31 PM - Abruptly retreated from its all-time high with a big volume-driven loss on the prior session. The 9/09/21 mid-day report last cautioned members - <i>&quot;Getting very extended from any sound base. Found support while consolidating above its 50 DMA line (113.44) in recent weeks. Reported Jun &#39;21 quarterly earnings +325% on +184% sales revenues versus the year ago period, marking its 4th consecutive quarterly comparison above the fact-based investment system&#39;s +25% minimum earnings guideline (C criteria). Patient investors may watch for a new base or secondary buy point to possibly develop and be noted in the weeks ahead. Went through a long and deep consolidation and rebounded impressively since noted with caution in the 11/29/19 mid-day report  - &#39;Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.&#39;&quot;</i><br><hr>9/9/2021 12:58:47 PM - Held its ground stubbornly and hit another new all-time high today, getting very extended from any sound base. Found support while consolidating above its 50 DMA line (113.44) in recent weeks. Reported Jun &#39;21 quarterly earnings +325% on +184% sales revenues versus the year ago period, marking its 4th consecutive quarterly comparison above the fact-based investment system&#39;s +25% minimum earnings guideline (C criteria). Patient investors may watch for a new base or secondary buy point to possibly develop and be noted in the weeks ahead. Went through a long and deep consolidation and rebounded impressively since noted with caution in the 11/29/19 mid-day report  - <i>&quot;Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.&quot;</i><br><hr>9/8/2021 12:08:04 PM - Holding its ground at its all-time high, very extended from any sound base. Found support while consolidating above its 50 DMA line (112.50) in recent weeks. Reported Jun &#39;21 quarterly earnings +325% on +184% sales revenues versus the year ago period, marking its 4th consecutive quarterly comparison above the fact-based investment system&#39;s +25% minimum earnings guideline (C criteria). Patient investors may watch for a new base or secondary buy point to possibly develop and be noted in the weeks ahead. Went through a long and deep consolidation and rebounded impressively since noted with caution in the 11/29/19 mid-day report  - <i>&quot;Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.&quot;</i><br><hr>8/27/2021 1:00:10 PM - Hitting another new high with today&#39;s 9th consecutive gain, very extended from any sound base. Found support while consolidating above its 50 DMA line in recent weeks. Reported Jun &#39;21 quarterly earnings +325% on +184% sales revenues versus the year ago period, marking its 4th consecutive quarterly comparison above the fact-based investment system&#39;s +25% minimum earnings guideline (C criteria). Patient investors may watch for a new base or secondary buy point to possibly develop and be noted in the weeks ahead. Went through a long and deep consolidation and rebounded impressively since noted with caution in the 11/29/19 mid-day report  - <i>&quot;Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.&quot;</i><br><hr>8/23/2021 12:31:31 PM - Hitting a new high today and getting very extended from any sound base. Found support while consolidating above its 50 DMA line in recent weeks. Reported Jun &#39;21 quarterly earnings +325% on +184% sales revenues versus the year ago period, marking its 4th consecutive quarterly comparison above the fact-based investment system&#39;s +25% minimum earnings guideline (C criteria). Patient investors may watch for a new base or secondary buy point to possibly develop and be noted in the weeks ahead. Went through a long and deep consolidation and rebounded impressively since noted with caution in the 11/29/19 mid-day report  - <i>&quot;Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.&quot;</i><br><hr>8/19/2021 12:18:28 PM - Extended from any sound base, it found support while consolidating above its 50 DMA line this week. Reported Jun &#39;21 quarterly earnings +325% on +184% sales revenues versus the year ago period, marking its 4th consecutive quarterly comparison above the fact-based investment system&#39;s +25% minimum earnings guideline (C criteria). Patient investors may watch for a new base or secondary buy point to possibly develop and be noted in the weeks ahead. Went through a long and deep consolidation and rebounded impressively since noted with caution in the 11/29/19 mid-day report  - <i>&quot;Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.&quot;</i><br><hr>8/11/2021 1:45:16 PM - Pulling back this week with volume-driven losses after getting extended from any sound base. Reported Jun &#39;21 quarterly earnings +325% on +184% sales revenues versus the year ago period, marking its 4th consecutive quarterly comparison above the fact-based investment system&#39;s +25% minimum earnings guideline (C criteria). Patient investors may watch for a new base or secondary buy point to possibly develop and be noted in the weeks ahead. Went through a long and deep consolidation and rebounded impressively since noted with caution in the 11/29/19 mid-day report  - <i>&quot;Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.&quot;</i><br><hr>7/28/2021 12:50:13 PM - It did not form  a sound base pattern but stubbornly held its ground after big volume-driven gains for new highs. Reported Jun &#39;21 quarterly earnings +325% on +184% sales revenues versus the year ago period, marking its 4th consecutive quarterly comparison above the fact-based investment system&#39;s +25% minimum earnings guideline (C criteria). Patient investors may watch for a new base or secondary buy point to possibly develop and be noted in the weeks ahead. Went through a long and deep consolidation and rebounded impressively since noted with caution in the 11/29/19 mid-day report  - <i>&quot;Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.&quot;</i><br><hr>7/13/2021 11:31:17 AM - It did not form  a sound base pattern but posted big volume-driven gains for new highs. Reported Mar &#39;21 quarterly earnings +130% on +62% sales revenues in the Mar &#39;21 quarter versus the year ago period, marking its 3rd consecutive quarterly comparison above the fact-based investment system&#39;s +25% minimum earnings guideline (C criteria). Patient investors may watch for a new base or secondary buy point to possibly develop and be noted in the weeks ahead. Went through a long and deep consolidation and rebounded impressively since noted with caution in the 11/29/19 mid-day report  - <i>&quot;Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.&quot;</i><br><hr>7/12/2021 12:54:30 PM - It did not form  a sound base pattern yet gapped up again today for a big volume-driven gain and new high. Reported Mar &#39;21 quarterly earnings +130% on +62% sales revenues in the Mar &#39;21 quarter versus the year ago period, marking its 3rd consecutive quarterly comparison above the fact-based investment system&#39;s +25% minimum earnings guideline (C criteria). Patient investors may watch for a new base or secondary buy point to possibly develop and be noted in the weeks ahead. Went through a long and deep consolidation and rebounded impressively since noted with caution in the 11/29/19 mid-day report  - <i>&quot;Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.&quot;</i><br><hr>7/6/2021 12:41:29 PM - It did not form  a sound base pattern yet volume totals have been cooling since a gap up and big volume-driven gain noted on 6/07/21. Reported Mar &#39;21 quarterly earnings +130% on +62% sales revenues in the Mar &#39;21 quarter versus the year ago period, marking its 3rd consecutive quarterly comparison above the fact-based investment system&#39;s +25% minimum earnings guideline (C criteria). Patient investors may watch for a new base or secondary buy point to possibly develop and be noted in the weeks ahead. Went through a long and deep consolidation and rebounded impressively since noted with caution in the 11/29/19 mid-day report  - <i>&quot;Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.&quot;</i><br><hr>6/15/2021 12:36:57 PM - It did not form  a sound base pattern yet stubbornly held its ground near its 52-week high with volume totals cooling since a gap up and big volume-driven gain noted on 6/07/21. Reported Mar &#39;21 quarterly earnings +130% on +62% sales revenues in the Mar &#39;21 quarter versus the year ago period, marking its 3rd consecutive quarterly comparison above the fact-based investment system&#39;s +25% minimum earnings guideline (C criteria). Patient investors may watch for a new base or secondary buy point to possibly develop and be noted in the weeks ahead. Went through a long and deep consolidation and rebounded impressively since noted with caution in the 11/29/19 mid-day report  - <i>&quot;Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.&quot;</i><br><hr>6/8/2021 12:30:11 PM - It did not form  a sound base pattern yet gapped up on the prior session hitting a new 52-week high with a big volume-driven gain. Reported Mar &#39;21 quarterly earnings +130% on +62% sales revenues in the Mar &#39;21 quarter versus the year ago period, marking its 3rd consecutive quarterly comparison above the fact-based investment system&#39;s +25% minimum earnings guideline (C criteria). Patient investors may watch for a new base or secondary buy point to possibly develop and be noted in the weeks ahead. Went through a long and deep consolidation and rebounded impressively since noted with caution in the 11/29/19 mid-day report  - <i>&quot;Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.&quot;</i><br><hr>6/7/2021 12:17:05 PM - It did not form  a sound base pattern yet gapped up today hitting a new 52-week high with today&#39;s big volume-driven gain. Reported Mar &#39;21 quarterly earnings +130% on +62% sales revenues in the Mar &#39;21 quarter versus the year ago period, marking its 3rd consecutive quarterly comparison above the fact-based investment system&#39;s +25% minimum earnings guideline (C criteria). Patient investors may watch for a new base or secondary buy point to possibly develop and be noted in the weeks ahead. Went through a long and deep consolidation and rebounded impressively since noted with caution in the 11/29/19 mid-day report  - <i>&quot;Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.&quot;</i><br><hr>5/5/2021 12:43:32 PM - Extended from any sound base and pulling back from its 52-week high with today&#39;s 6th consecutive loss. Found support at its 50 DMA line ($76.98) during its prior consolidation. Reported Mar &#39;21 quarterly earnings +130% on +62% sales revenues in the Mar &#39;21 quarter versus the year ago period, marking its 3rd consecutive quarterly comparison above the fact-based investment system&#39;s +25% minimum earnings guideline (C criteria). Patient investors may watch for a new base or secondary buy point to possibly develop and be noted in the weeks ahead. Went through a long and deep consolidation and rebounded impressively since noted with caution in the 11/29/19 mid-day report  - <i>&quot;Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.&quot;</i><br><hr>4/27/2021 12:40:29 PM - Extended from any sound base and hitting yet another new 52-week high with today&#39;s 3rd consecutive gain, wedging higher. Found support at its 50 DMA line during its consolidation since noted with caution in the 3/04/21  mid-day report - <i>"Earnings improved +104% on +60% sales revenues in the Dec &#39;20 quarter versus the year ago period. Prior earnings history is not a match with the fact-based investment system&#39;s fundamental guidelines (C and A criteria). Went through a deep consolidation and rebounded impressively since noted with caution in the 11/29/19 mid-day report  - &#39;Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.&#39;"</i><br><hr>4/15/2021 12:32:25 PM - Hitting yet another new 52-week high with today&#39;s gain after wedging higher last week. Found support at its 50 DMA line ($71.96) during its consolidation since noted with caution in the 3/04/21  mid-day report - <i>&quot;Earnings improved +104% on +60% sales revenues in the Dec &#39;20 quarter versus the year ago period. Prior earnings history is not a match with the fact-based investment system&#39;s fundamental guidelines (C and A criteria). Went through a deep consolidation and rebounded impressively since noted with caution in the 11/29/19 mid-day report  - &#39;Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.&#39;&quot;</i><br><hr>4/12/2021 12:44:48 PM - Hitting another new 52-week high with today&#39;s small gain after wedging higher last week. Found support at its 50 DMA line ($70.53) during its consolidation since last noted with caution in the 3/04/21  mid-day report - <i>&quot;Earnings improved +104% on +60% sales revenues in the Dec &#39;20 quarter versus the year ago period. Prior earnings history is not a match with the fact-based investment system&#39;s fundamental guidelines (C and A criteria). Went through a deep consolidation and rebounded impressively since noted with caution in the 11/29/19 mid-day report  - &#39;Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.&#39;&quot;</i><br><hr>3/4/2021 12:52:52 PM - Pulling back from its 52-week high with today&#39;s 2nd consecutive volume-driven loss, negating a recent breakout from a tight consolidation of the prior 3 weeks. Prior mid-day reports noted - <i>"Earnings improved +104% on +60% sales revenues in the Dec &#39;20 quarter versus the year ago period. Prior earnings history is not a match with the fact-based investment system&#39;s fundamental guidelines (C and A criteria). Went through a deep consolidation and rebounded impressively since noted with caution in the 11/29/19 mid-day report  - &#39;Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.&#39;"</i><br><hr>3/3/2021 12:38:01 PM - Powering to new 52-week highs with today&#39;s 4th consecutive volume-driven gain, getting extended from the tight consolidation of the prior 3 weeks. Prior mid-day reports noted - <i>&quot;Earnings improved +104% on +60% sales revenues in the Dec &#39;20 quarter versus the year ago period. Prior earnings history is not a match with the fact-based investment system&#39;s fundamental guidelines (C and A criteria). Went through a deep consolidation and rebounded impressively since noted with caution in the 11/29/19 mid-day report  - &#39;Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.&#39;&quot;</i><br><hr>3/2/2021 12:41:42 PM - Powering to new 52-week highs with today&#39;s 3rd consecutive volume-driven gain, getting extended from the tight consolidation of the past 3 weeks. Prior mid-day reports noted - <i>"Earnings improved +104% on +60% sales revenues in the Dec &#39;20 quarter versus the year ago period. Prior earnings history is not a match with the fact-based investment system&#39;s fundamental guidelines (C and A criteria). Went through a deep consolidation and rebounded impressively since noted with caution in the 11/29/19 mid-day report  - &#39;Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.&#39;"</i><br><hr>3/1/2021 12:51:11 PM - Challenging its 52-week high with today&#39;s big volume-driven gain following a tight consolidation for the past 3 weeks. The 2/23/21 mid-day report last noted - <i>&quot;Earnings improved +104% on +60% sales revenues in the Dec &#39;20 quarter versus the year ago period. Prior earnings history is not a match with the fact-based investment system&#39;s fundamental guidelines (C and A criteria). Went through a deep consolidation and rebounded impressively since noted with caution in the 11/29/19 mid-day report  - &#39;Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.&#39;&quot;</i><br><hr>2/23/2021 12:57:57 PM - Hovering near its 52-week high in a tight range for the past 3 weeks. Prior mid-day reports noted - <i>"Earnings improved +104% on +60% sales revenues in the Dec &#39;20 quarter versus the year ago period. Prior earnings history is not a match with the fact-based investment system&#39;s fundamental guidelines (C and A criteria). Went through a deep consolidation and rebounded impressively since noted with caution in the 11/29/19 mid-day report  - &#39;Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.&#39;"</i><br><hr>2/19/2021 12:44:57 PM - Very extended from any sound base, hovering near its 52-week high with volume totals cooling since noted in the 2/11/21 mid-day report - <i>"Earnings improved +104% on +60% sales revenues in the Dec &#39;20 quarter versus the year ago period. Prior earnings history is not a match with the fact-based investment system&#39;s fundamental guidelines (C and A criteria). Went through a deep consolidation and rebounded impressively since noted with caution in the 11/29/19 mid-day report  - &#39;Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.&#39;"</i><br><hr>2/18/2021 12:45:01 PM - Very extended from any sound base, hovering near its 52-week high with volume totals cooling since last noted in the 2/11/21 mid-day report - <i>&quot;Earnings improved +104% on +60% sales revenues in the Dec &#39;20 quarter versus the year ago period. Prior earnings history is not a match with the fact-based investment system&#39;s fundamental guidelines (C and A criteria). Went through a deep consolidation and rebounded impressively since noted with caution in the 11/29/19 mid-day report  - &#39;Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.&#39;&quot;</i><br><hr>2/11/2021 1:15:44 PM - Very extended from any sound base, retreating from a new 52-week high hit on the prior session. Earnings improved +104% on +60% sales revenues in the Dec &#39;20 quarter versus the year ago period. Prior earnings history is not a match with the fact-based investment system&#39;s fundamental guidelines (C and A criteria). Went through a deep consolidation and rebounded impressively since noted with caution in the 11/29/19 mid-day report  - <i>&quot;Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.&quot;</i><br><hr>1/13/2021 1:01:02 PM - Hitting new 52-week highs with recent volume-driven gains, very extended from any sound base. Earnings improved +26% on +49% sales revenues in the Sep &#39;20 quarter versus the year ago period. Prior earnings history is not a match with the fact-based investment system&#39;s fundamental guidelines (C and A criteria). Went through a deep consolidation since noted with caution in the 11/29/19 mid-day report  - <i>&quot;Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.&quot;</i><br><hr>1/7/2021 12:52:58 PM - Earnings improved +26% on +49% sales revenues in the Sep &#39;20 quarter versus the year ago period. Prior earnings history is not a match with the fact-based investment system&#39;s fundamental guidelines (C and A criteria). Went through a deep consolidation since noted with caution in the 11/29/19 mid-day report  - <i>&quot;Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.&quot;</i><br><hr>12/14/2020 12:39:53 PM - Earnings improved +26% on +49% sales revenues in the Sep &#39;20 quarter versus the year ago period. Prior earnings history is not a match with the fact-based investment system&#39;s fundamental guidelines (C and A criteria). Went through a deep consolidation since last noted with caution in the 11/29/19 mid-day report  - <i>&quot;Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.&quot;</i><br><hr>11/29/2019 11:07:39 AM - Extended from any sound base, consolidating after an impressive spurt of volume-driven gains. Earnings improved +77% on +57% sales revenues in the Sep &#39;19 quarterly comparison. Prior reports noted - <i>&quot;Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.&quot;</i><br><hr>11/27/2019 11:58:20 AM - Extended from any sound base, consolidating after an impressive spurt of volume-driven gains. Earnings improved +77% on +57% sales revenues in the Sep &#39;19 quarterly comparison. Prior reports noted - <i>&quot;Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.&quot;</i><br><hr>11/19/2019 1:59:32 PM - Perched at its 52-week high today and adding to an impressive spurt of volume-driven gains. Earnings improved +77% on +57% sales revenues in the Sep &#39;19 quarterly comparison. Prior reports noted - <i>&quot;Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.&quot;</i><br><hr>11/18/2019 12:14:14 PM - Hitting yet another new 52-week high today adding to an impressive spurt of volume-driven gains. Earnings improved +77% on +57% sales revenues in the Sep &#39;19 quarterly comparison. Prior reports noted - <i>&quot;Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.&quot;</i><br><hr>11/15/2019 11:59:55 AM - Hitting yet another new 52-week high today adding to an impressive spurt of volume-driven gains. Earnings improved +77% on +57% sales revenues in the Sep &#39;19 quarterly comparison. Prior reports noted - <i>&quot;Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.&quot;</i><br><hr>11/13/2019 12:28:57 PM - There was a &quot;negative reversal&quot; after hitting yet another new 52-week high on the prior session following an impressive spurt of volume-driven gains. Earnings improved +77% on +57% sales revenues in the Sep &#39;19 quarterly comparison. Prior reports noted - <i>&quot;Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.&quot;</i><br><hr>11/12/2019 12:37:36 PM - Reversed into the red after hitting yet another new 52-week high today following an impressive spurt of volume-driven gains. Earnings improved +77% on +57% sales revenues in the Sep &#39;19 quarterly comparison. Prior reports noted - <i>&quot;Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.&quot;</i><br><hr>11/11/2019 1:05:10 PM - Hitting another new 52-week high today while adding to an impressive spurt of volume-driven gains. Earnings improved +77% on +57% sales revenues in the Sep &#39;19 quarterly comparison. Prior reports noted - <i>&quot;Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.&quot;</i><br><hr>11/8/2019 12:32:04 PM - Hitting another new 52-week high today while adding to an impressive spurt of volume-driven gains. Earnings improved +77% on +57% sales revenues in the Sep &#39;19 quarterly comparison. Prior reports noted - <i>&quot;Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.&quot;</i><br><hr>11/6/2019 12:21:13 PM - Retreating from a new 52-week high following 2 consecutive gaps up and big volume-driven gains. Earnings improved +77% on +57% sales revenues in the Sep &#39;19 quarterly comparison. Prior reports noted - <i>&quot;Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.&quot;</i><br><hr>11/5/2019 12:41:04 PM - Hitting another new 52-week high with today&#39;s 2nd consecutive gap up and big volume-driven gain. Earnings improved +77% on +57% sales revenues in the Sep &#39;19 quarterly comparison. Prior reports noted - <i>&quot;Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.&quot;</i><br><hr>11/4/2019 12:14:53 PM - Hitting another new 52-week high with today&#39;s gap up and big volume-driven gain. Due to report earnings news.  Prior mid-day reports noted - <i>&quot;Earnings improved +100% on +55% sales revenues in the Jun &#39;19 quarterly comparison.  Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.&quot; </i><br><hr>10/23/2019 12:34:54 PM - Hitting another new 52-week high with today&#39;s 2nd consecutive volume-driven gain. Earnings improved +100% on +55% sales revenues in the Jun &#39;19 quarterly comparison.  Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.<br><hr>10/22/2019 12:35:20 PM - Hitting a new 52-week high with today&#39;s volume-driven gain. Earnings improved +100% on +55% sales revenues in the Jun &#39;19 quarterly comparison.  Limited history is a concern for this Israel-based Medical -  Systems/Equipment firm since its $14 IPO on 8/08/19.<br><hr>6/13/2012 12:01:45 PM - Holding its ground perched at its 52-week high following a gap up on 6/11/12 from below its 50 DMA line after it agreed to be Acquired by Sagard Capital Partners for <strong>$169.5</strong> Million. Earnings improved <strong>+38%</strong> on <strong>+10%</strong> sales revenues in the Mar &#39;12 quarterly comparison, making it <strong>3</strong> consecutive quarters with earnings increases above the <strong>+25%</strong> guideline for the <strong>C</strong> criteria. The 5/11/12 mid-day report noted - <em>&quot;The low-priced stock hailing from the Medical - Services industry group has questionable fundamentals after a lackluster growth rate in recent years (<strong>A</strong> criteria). It showed promising technical action in recent months as it rallied to multi-year highs.&quot; </em><br><hr>6/12/2012 12:14:27 PM - Perched near its 52-week high following a gap up on 6/11/12 from below its 50 DMA line after it agreed to be Acquired by Sagard Capital Partners for <strong>$169.5</strong> Million. Earnings improved <strong>+38%</strong> on <strong>+10%</strong> sales revenues in the Mar &#39;12 quarterly comparison, making it <strong>3</strong> consecutive quarters with earnings increases above the <strong>+25%</strong> guideline for the <strong>C</strong> criteria. The 5/11/12 mid-day report noted - <em>&quot;The low-priced stock hailing from the Medical - Services industry group has questionable fundamentals after a lackluster growth rate in recent years (<strong>A</strong> criteria). It showed promising technical action in recent months as it rallied to multi-year highs.&quot; </em><br><hr>6/11/2012 12:12:18 PM - Gapped up today from below its 50 DMA line and hit a new 52-week high after it agreed to be Acquired by Sagard Capital Partners for <strong>$169.5</strong> Million. Earnings improved <strong>+38%</strong> on <strong>+10%</strong> sales revenues in the Mar &#39;12 quarterly comparison, making it <strong>3</strong> consecutive quarters with earnings increases above the <strong>+25%</strong> guideline for the <strong>C</strong> criteria. Last noted in the 5/11/12 mid-day report - <em>&quot;The low-priced stock hailing from the Medical - Services industry group has questionable fundamentals after a lackluster growth rate in recent years (<strong>A</strong> criteria). It showed promising technical action in recent months as it rallied to multi-year highs.&quot; </em><br><hr>5/11/2012 12:25:42 PM - Earnings improved <strong>+38%</strong> on <strong>+10%</strong> sales revenues in the Mar &#39;12 quarterly comparison, making it <strong>3</strong> consecutive quarters with earnings increases above the <strong>+25%</strong> guideline for the <strong>C</strong> criteria.  Consolidating above its 50 DMA line with recent gains lacking volume conviction since the 4/18/12 mid-day report noted - <em>&quot;The low-priced stock hailing from the Medical - Services industry group has questionable fundamentals after a lackluster growth rate in recent years (<strong>A</strong> criteria). It showed promising technical action in recent months as it rallied to multi-year highs.&quot; </em><br><hr>4/18/2012 12:24:39 PM - Earnings improved in the Sep and Dec &#39;11 quarterly comparisons. The low-priced stock hailing from the Medical - Services industry group has questionable fundamentals after a lackluster growth rate in recent years (<strong>A</strong> criteria).  It showed promising technical action in recent months as it rallied to multi-year highs.<br><hr>10/18/2007 12:57:17 PM - Questionable fundamentals, but promising technical action.  It has formed a 10-month long flat base and traded up to new highs this week with volume picking up.<br><hr>10/17/2007 1:34:20 PM - Questionable fundamentals, but promising technical action.  It has formed a 10-month long flat base and traded up to new highs this week with volume picking up.<br><hr>